多发性骨髓瘤IL-6及受体的检测及意义

Detection of IL-6 and its Receptor in Multiple Myeloma Patients

[目的]为了比较不同阶段多发性骨髓瘤(MM)病人血清IL 6及可溶性受体sIL 6R水平与疾病活动性及预后之间的关系。[方法]对16名良性骨肿瘤病人、15名多发性骨髓瘤稳定期病人、29名MM进展期及正常人之间血清IL 6、sIL 6R水平进行了比较 ,采用ELISA方法测定浓度水平 ,两组间差异采用t检验方法。[结果]两指标在各组间存在明显的差别 (P<0.05) ,同时 ,在对29名多发性骨髓瘤的随访治疗过程中 ,18名有效病人的IL 6、sIL 6R在治疗前后存在明显差异 ,而在无效和死亡的病人中 ,治疗前后无明显差别。[结论]IL 6及sIL 6R水平与疾病的严重程度密切相关 。

To compare the serum level of IL-6 and sIL-6R in different stage of Mutiple Myeloma(MM) patients, and to evaluate the relationship among the level of serum and the activity of disease, and the prognosis of MM. The level of IL-6 and sIL-6R among 16 cases with osteoma, 15 cases with MM at stabilization, 29 cases with MM at developing stage and 20 cases of normal persons were compared.ELISA method was used. Difference among groups was examined by t-test. The level of IL-6 and sIL-6R among various groups were significantly different . The levels of IL-6 and sIL-6R before and after therapy were statistically different in 18 of 29 cases with developing MM during follow-up. No significant difference was found in inefficiency or died patients after therapy.[Conclusion] The levels of IL-6 and sIL-6R have a significant relationship to the severity of MM, and can be important indexes in evaluating the severity of disease and the prognosis.